# Efficacy and Safety of Increased Dose of TA-650(Infliximab) in Patients With Rheumatoid Arthritis

> **NCT00691028** · PHASE3 · COMPLETED · sponsor: **Tanabe Pharma Corporation** · enrollment: 327 (actual)

## Conditions studied

- Rheumatoid Arthritis

## Interventions

- **DRUG:** TA-650 3 mg/kg
- **DRUG:** TA-650 6 mg/kg
- **DRUG:** TA-650 10 mg/kg

## Key facts

- **NCT ID:** NCT00691028
- **Lead sponsor:** Tanabe Pharma Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-09
- **Primary completion:** 2007-05
- **Final completion:** 2007-05
- **Target enrollment:** 327 (ACTUAL)
- **Last updated:** 2026-01-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00691028

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00691028, "Efficacy and Safety of Increased Dose of TA-650(Infliximab) in Patients With Rheumatoid Arthritis". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00691028. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*